What “Vesanoid” trials are being referred to?
“Vesanoid” is the brand name for tretinoin (all-trans retinoic acid, ATRA), best known for its role in acute promyelocytic leukemia (APL). The most commonly referenced “Vesanoid clinical trial” in medical and historical searches is the early clinical evidence showing that ATRA could induce remission in APL patients.
Which diseases did Vesanoid (tretinoin/ATRA) clinical trials target?
ATRA (Vesanoid) trials primarily targeted acute promyelocytic leukemia (APL). These studies focused on whether tretinoin could drive differentiation of the leukemic promyelocytes and achieve remission.
Why did early Vesanoid/ATRA trials matter in APL?
APL was previously associated with very high mortality from disease complications. Clinical investigation of ATRA aimed to determine whether differentiating therapy could produce measurable remission rates and improve survival compared with then-standard approaches.
What endpoints did Vesanoid trials typically measure?
APL ATRA studies generally tracked clinical and hematologic outcomes such as:
- Remission/response rates (including molecular or hematologic response, depending on the study design)
- Time to response
- Treatment-related toxicities (including differentiation-related complications)
- Survival outcomes (overall survival and/or event-free survival, depending on trial phase)
What kinds of risks were associated with APL tretinoin (Vesanoid) treatment?
In APL specifically, ATRA is known to carry risks linked to the differentiation process and supportive-care needs, which trials monitored closely. The main safety questions in APL ATRA research center on complications that can occur early during treatment and require rapid management.
How to find the exact “Vesanoid clinical trial” you mean
Searchers often use one of these variations, each pointing to different documents/trial phases:
- “Vesanoid APL trial”
- “ATRA tretinoin induction remission trial”
- “all-trans retinoic acid trial acute promyelocytic leukemia”
- “Vesanoid randomized trial”
If you share any extra detail (for example, the year, the journal name, the country, or the trial identifier like NCT number), I can narrow to the specific study and summarize its design and results.
Source note
No trial-specific clinical results were provided in your prompt, and there’s no DrugPatentWatch.com trial entry you referenced. If you want patent/exclusivity context for Vesanoid (tretinoin), share the indication or country, and I can look for the relevant patent/exclusivity record.